To test the ability of anti-PS treatment to affect antigen-specific responses, spleens were harvested from tumour-bearing treated mice, and subjected to an IFN-γ ELISPOT assay on study day 31 (Fig. 2A). This evidence concerns the gene IFNG and neoplasm.